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Background-—Several metabolic conditions can cause the Brugada ECG pattern, also called Brugada phenotype (BrPh). We aimed
to define the clinical characteristics and outcome of BrPh patients and elucidate the mechanisms underlying BrPh attributed to
hyperkalemia.
Methods and Results-—We prospectively identified patients hospitalized with severe hyperkalemia and ECG diagnosis of BrPh and
compared their clinical characteristics and outcome with patients with hyperkalemia but no BrPh ECG. Computer simulations
investigated the roles of extracellular potassium increase, fibrosis at the right ventricular outflow tract, and epicardial/endocardial
gradients in transient outward current. Over a 6-year period, 15 patients presented severe hyperkalemia with BrPh ECG that was
transient and disappeared after normalization of their serum potassium. Most patients were admitted because of various severe
medical conditions causing hyperkalemia. Six (40%) patients presented malignant arrhythmias and 6 died during admission. Multiple
logistic regression analysis revealed that higher serum potassium levels (odds ratio, 15.8; 95% CI, 3.1–79; P=0.001) and male sex
(odds ratio, 17; 95% CI, 1.05–286; P=0.045) were risk factors for developing BrPh ECG in patients with severe hyperkalemia. In
simulations, hyperkalemia yielded BrPh by promoting delayed and heterogeneous right ventricular outflow tract activation attributed
to elevation of resting potential, reduced availability of inward sodium channel conductance, and increased right ventricular outflow
tract fibrosis. An elevated transient outward current gradient contributed to, but was not essential for, the BrPh phenotype.
Conclusions-—In patients with severe hyperkalemia, a BrPh ECG is associated with malignant arrhythmias and all-cause mortality
secondary to resting potential depolarization, reduced sodium current availability, and fibrosis at the right ventricular outflow tract.
( J Am Heart Assoc. 2019;8:e010115. DOI: 10.1161/JAHA.118.010115.)
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B rugada syndrome (BrS) is characterized by distinctive ST-segment elevation in the right precordial leads of the
ECG, and propensity for sudden cardiac death.1,2 According to
the 2013 consensus statement on cardiac arrhythmia
syndromes and the 2016 J-Wave syndromes expert consen-
sus conference report, BrS is diagnosed in patients with
spontaneous ST-segment elevation (≥2 mm) with type 1
morphology in ≥1 precordial leads, particularly V1 and V2,
positioned on the second and third or fourth intercostal
spaces.3,4 BrS has been considered as a primary electric
cardiac disease caused by mutations in genes coding sodium,
calcium, and potassium channels in 30% of patients.3–5
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However, other studies found no clear genetic association,
and minor structural abnormalities were associated with the
syndrome.6–8 Moreover, some environmental factors can
induce ECG morphologies similar or identical to BrS in the
absence of genetic mutations or ion-channel dysfunction.6,9
The acquired form of Brugada-like ECG pattern, also called
Brugada phenotype (BrPh), is manifested by a Brugada ECG
pattern in the presence of an identifiable underlying condition
and typically disappears after its resolution.3,4,10–12 Multiple
metabolic conditions can lead to BrPh ECG; the majority of
cases are associated with serum K+ abnormalities, hyper-
kalemia being the most frequent single cause.10 Although
classical hyperkalemia produces several well-described ECG
alterations, only a minority of patients develop BrPh.10,12
Nevertheless, the clinical characteristics and prognostic
impact on patients developing BrPh are poorly known.
The main mechanism responsible for BrS phenotype relate
to abnormal patterns of repolarization and/or impulse
activation at the right ventricular outflow tract (RVOT).13–16
However, whether BrPh represents transient alterations in
myocardial depolarization, repolarization, or any other mech-
anism is yet to be elucidated. Moreover, the transient nature
of BrPh casts doubt about its genetic origin or relation to
structural abnormalities, or both.
The objectives of the study were several fold, including to:
(1) describe the clinical and ECG characteristics and clinical
outcome of patients with hyperkalemic BrPh; (2) compare the
clinical characteristics of patients with hyperkalemic BrPh
with those of patients with severe hyperkalemia but no BrPh
ECG; (3) conduct computer simulations in a three-dimensional
model of ventricular propagation under conditions of varying
hyperkalemia to analyze the implication of mutations and/or
structural abnormalities in relation to the Brugada sign17;
(4) study the mechanisms underlying hyperkalemic BrPh; and
(5) evaluate the proarrhythmic risk of BrPh in the presence of
hyperkalemia.
Methods
Data, analytical methods, and study materials will be made
available to other researchers for purposes of reproducing the
results or replicating the procedure. The data will be made
available for requests made to corresponding author by
e-mail.
Patients
From 2010 to 2016, we prospectively identified patients
hospitalized at our institution who presented an ECG suggestive
of BrS in the context of severe hyperkalemia (group 1). Inclusion
in this series requiredmoderate-to-severe hyperkalemia (serum
potassium [K+] ≥6.5 mmol/L), hospitalization for an acute
illness and type 1 or 2 Brugada ECG pattern on right precordial
leads V1 to V2, which normalized after serum K+ levels returned
to reference values.10 Additionally, we also considered patients
with atypical ST-segment elevation on the right precordial leads
without BrS and/or aVR sign.18,19 Furthermore, we retrospec-
tively reviewed the charts of all adults admitted to our center
during 2013 who developed severe hyperkalemia any time
during admission, with an available ECG recording at peak
serum K+ ≥6.5 mmol/L (group 2).
For all patients, we recorded demographic and clinical
characteristics, laboratory data, treatments, and hospital
outcomes, including diagnosis at discharge and survival
status. The ECGs obtained during peak serum K+ were
analyzed for rate, rhythm, P-wave voltage, PR interval
duration, QRS width, QRS axis, QTc interval, maximum height
of ST-segment elevation, and T wave height. In group 1
patients, the recorded ECGs were compared before and after
treatment of hyperkalemia. In group 1 patients displaying a
BrPh ECG, a provocative flecainide test was performed after
normalization of the electrolyte disturbances. Patients were
considered to be at a low clinical probability of having BrS if
they had a negative flecainide challenge test, a lack of
family history of syncope or sudden death, no previous
history of syncope or cardiac arrhythmia, and normal body
temperature.10 The institutional review board of our center
waived the informed consent form and approved the study.
Clinical Perspective
What Is New?
• In patients with severe hyperkalemia resulting from a critical
medical condition, the presence of a Brugada syndrome
ECG phenotype is associated with a high prevalence of
malignant arrhythmias and all-cause mortality.
• Higher serum potassium levels and male sex are indepen-
dent predictors for the presence of a Brugada ECG
phenotype.
• Modeling studies indicate that the Brugada ECG phenotype
induced by severe hyperkalemia occurs secondary to
membrane depolarization and consequent reduced sodium
channel availability, resulting in delayed and heterogeneous
conduction, particularly in the presence of fibrosis at the
right ventricular outflow tract.
What Are the Clinical Implications?
• Prompt recognition of this clinical-morphological entity and
immediate treatment of hyperkalemia and surveillance of
potential life-threatening arrhythmias is strongly
recommended.
• Drug-provocation testing following normalization of serum
potassium levels may be considered to uncover underlying
Brugada syndrome.
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Computer Simulations
A multiscale computer model was constructed to determine
conditions for the BrPh ECG in patients with hyperkalemia.
The model was based on several parameters, including
electrophysiological dynamics, transmural differences in cell
type, fiber orientation, and fibrosis at varying extracellular
potassium concentrations ([K+]o) ranging between 5.4 and
10.5 mmol/L. A human wedge model of the anterior ventric-
ular wall, including both ventricles and the RVOT, was created
using a reference geometry (normal young male), available for
the ECGSIM software.20 The mesh contained 281 191 nodes
and 1 460 832 elements with a mean edge length of
290.8296.6 lm. Human ventricular cell dynamics and action
potential morphologies of cell types were simulated using the
O’Hara–Rudy model,21 with modifications in the sodium current
suggested by Dutta et al,22 which enabled realistic simulations
under hyperkalemic conditions. Ventricular activation
sequences were based on Cardone-Noott et al,23 being
initiated in 3 areas in our model. Anisotropic conduction
attributed to fiber orientation changes was incorporated into
the model using an anisotropy ratio of 10:1, D||:D⊥, where D||
and D⊥ are the longitudinal and transverse diffusion coeffi-
cients, respectively. Therefore, propagation in any direction of
the three-dimensional model depended on fiber direction. The
RVOT diffusion coefficient was 25% of either ventricle, keeping
the same anisotropy ratio.
Simulations were performed under 4 different conditions:
(1) healthy RVOT; (2) fibrotic RVOT; (3) RVOT with a gradient
of transient outward potassium current (Ito); and (4) fibrotic
RVOT with an epi- to endocardium Ito gradient. Various [K
+]o
concentrations (5.4, 7.5, 10.0, and 10.5 mmol/L) were
chosen considering that the level of serum K+ registered in
patients could be lower than in the extracellular space.24
Different [K+]o were tested in basal conditions and RVOT with
65% of fibrotic tissue. Fibrotic tissue was modeled by
randomly disconnecting a specific percentage of available
nodes in the RVOT. The enhanced Ito conductance gradient
was established by increasing the maximal conductance of
the current on the epicardium of the RVOT, from its basal level
(0.08 mS/lF) to 0.30, 0.70, and 1.50 mS/lF; these values
were consistent with experimentally derived data related to
BrS.25 Different cases were tested, combining the amount of
fibrosis (55, 65, and 75%), [K+]o concentrations (5.4 and
Figure 1. ECG recordings of patients displaying brugada ECG pattern at the time of peak hyperkalemia (precordial and aVR leads).
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10.5 mmol/L), and increasing Ito conductance gradient from
baseline to the maximal conductance, 1.50 mS/lF. Mon-
odomain equations were solved using the Forward-Euler
algorithm with a fixed time step of 0.01 ms on a graphic
processors unit (GPU Tesla K20 5GRAM DDR5).26 Three
virtual electrodes were positioned at standard electrode
locations for the calculation of pseudo-ECGs V1, V2, and V3.
Statistical Analyses
Categorical variables are reported as number and percentage
and were compared using Fisher’s exact test or the chi-square
test, as appropriate. For continuous variables, normal distri-
bution was assessed by the Kolmogorov–Smirnov test and are
reported as meanSD or median and interquartile range,
depending on whether they were normally or non-normally
distributed. Continuous variables comparisons were made
using the Student t test or nonparametric tests, as appropri-
ate. Multiple logistic regression analysis was performed to
identify predictors of a BrPh ECG in patients with severe
hyperkalemia. Analyses were performed using SPSS software
(version 22; SPSS, Inc, Chicago, IL), and statistical signifi-
cance was established at P<0.05.
Results
Clinical Characteristics and Outcome of Patients
With Hyperkalemic BrPh
During a 6-year observation period, we identified 15 patients
with severe hyperkalemia and type 1 or 2 ECG Brugada
pattern or atypical repolarization signs on the right precordial
leads (ST-segment elevation on the right precordial leads
pattern).3,4,18 Figure 1 shows ECG data from precordial lead
recordings from each patient displaying a BrPh ECG at the
time of peak hyperkalemia. None of the patients had a family
history of BrS, cardiac arrhythmias, or syncope. Baseline
clinical characteristics, hospital admission reason, and etiol-
ogy of hyperkalemia are shown in Table 1. In all cases, ECG
changes were transient and disappeared after plasma serum
K+ levels returned to normal (Table 2).
Most patients were middle aged (56.416 years old) men
(79%), presenting a critically ill state on admission. In fact, 3
were brought to the emergency room because of out-of-
hospital sudden cardiac arrest. The most frequent primary
etiology of hyperkalemia was decompensated renal function.
Six (43%) patients died during admission for different reasons
(Table 1): Two patients presented postanoxic encephalopathy,
Table 1. Clinical Characteristics and Outcome of Patients With Brugada Phenotype
Pt Sex Age, y K+ (mmol/L)
Hospital Admission
Reason Hyperkalemia Etiology Flecainide Test Diagnosis Outcome
1 F 62 8.2 OH SCD Potassium
supplements overdose
No Suicide Death
2 M 89 7.4 Diarrhea dehydration CKD descompensation No* Gastrointestinal infection Alive
3 M 45 7.7 Decompensated
liver cirrhosis
AKD No Terminal liver disease Death, 3 months
after discharge
4 M 53 6.9 DKA AKD Yes DKA, BrS Alive
5 F 83 9.1 OH SCD ≥2 RAAS inhibitors No Hyperkalemia Death
6 M 63 8.6 Sepsis AKD
Espironolactone
No Bilateral pneumonia Death
7 M 41 7.7 OH SCD AKD No Benzodiazepine overdose Death
8 M 38 7.2 Dehydration AKD Yes Gastrointestinal infection Alive




10 M 61 6.8 Lung cancer surgery IV fluid overdose Yes Lung cancer Alive
11 M 78 8.5 Diarrhea dehydration AKD Yes Gastrointestinal infection Alive
12 M 54 7.5 Acute renal disease AKD No* Gastrointestinal infection Alive
13 M 35 8.1 Abdominal cancer AKD No Metastatic testicular cancer Death
14 M 41 8.6 Sepsis CKD No* Sepsis Alive
15 M 46 7.7 DKA AKD Yes DKA Alive
≥2 RAAS inhibitors indicates combination of ≥2 ACE inhibitor, angiotensin II–receptor blocker, aldosterone antagonist, or renin inhibitors; AKD, acute kidney disease; BrS, Brugada
syndrome; CKD, chronic kidney disease; DKA, diabetic ketoacidosis; OH SCD, out-of-hospital sudden cardiac death.
*Flecainide test not performed because of clinical reasons or living overseas.
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1 had recurrent cardiac arrest at the time of arrival in the
emergency room, and 2 presented septic shock (patients 6
and 9). One patient died after prolonged admission because of
metastatic testicular cancer. Patient 3 died 3 months after
hospital discharge because of terminal hepatic disease.
We contacted 8 of the surviving patients, and a flecainide
test was finally performed in 5 (of the other 3, 1 was dismissed
because of severe neurologic chronic sequelae and 2 lived
overseas). The flecainide test was negative in 4 patients and
positive in 1. Patient 4 was a 53-year-old male admitted for
diabetic ketoacidosis with hyperkalemia (K+, 6.9 mmol/L;
serum pH, 6.89). He presented a BrPh pattern on admission
(Figure 2A), which was normalized after correction of the
serum K+ (4.5 mmol/L; serum pH, 7.1; Figure 2B). Several
weeks after hospital discharge, while the patient was clinically
stable, a flecainide test (2-mg/kg intravenous infusion over
10 minutes) uncovered a type 1 Brugada pattern (Figure 2C).
Clinical Characteristics and Outcome of Patients
With Hyperkalemic BrPh Versus Severe
Hyperkalemia With Non-BrPh Pattern
During 2013, 245 patients presented severe hyperkalemia of
46 459 admitted to our institution (0.53%). Of those, 44 (18%)
had an ECG recording available at the time of peak hyper-
kalemia. Table 3 shows baseline characteristics of BrPh
patients (group 1) and severe hyperkalemic patients without
BrPh (group 2). Compared with group 2 patients, BrPh patients
were younger and had higher serum K+ values (1 mmol/L
higher on average), lower pH, and less chronic kidney disease;
hypertension tended to be less prevalent and so was the use of
angiotensin-receptor blockers. On ECG, BrPh hyperkalemic
patients showed wider QRS, and frequently presented abnor-
mal QRS axis and greater T-wave height compared with non-
BrPh hyperkalemic patients (Table 3). Multivariate analysis
Figure 2. Brugada pattern uncovered by hyperkalemia in a patient with Brugada syndrome. A, Patient previously asymptomatic, admitted
because of diabetic ketoacidosis, displaying an ECG Brugada pattern. B, ECG normalized after correction of the electrolyte disturbances.
C, Baseline ECG and following infusion of Flecainide.
Table 2. Electrocardiographic Characteristics at Peak K+ Levels and Following K+ Levels Normalization in Patients Displaying a
Brugada ECG Pattern Recording
ECG at Peak Hyperkalemia
Brugada Phenotype (n=15) ECG After K levels Normalization (n=15) P Value
Heart rate, bpm, median (IQR) 89 (26) 60 (60–89) 0.08
P-wave voltage, mm, median (IQR) 0.5 (0.5–1) 1 (0.5–1.3) 0.13
PR segment, ms, median (IQR) 160 (160–220) 160 (130–190) 0.27
QRS abnormal axis, n (%) 9 (60) 2 (16) 0.04
QRS width, ms, median (IQR) 120 (110–160) 80 (80–120) 0.001
QTc segment, ms, median (IQR) 433 (69) 420 (395–430) 0.58
T wave height, mm, median (IQR) 7 (5–14) 3 (3–6) 0.002
IQR indicates interquartile range; K, potassium.
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revealed that higher serum K+ levels (odds ratio, 15.8; 95% CI,
3.1–79; P=0.001) and male sex (odds ratio, 17; 95% CI, 1.05–
286; P=0.045) were independent predictors for developing
BrPh ECG in patients with severe hyperkalemia. Moreover,
lower arterial pH, available in a smaller number of patient
samples, was also related to development of BrPh ECG
(Tables 3 and 4).
Of 15 patients with BrPh, 6 (40%) had malignant arrhyth-
mias (3 presented as sudden cardiac arrest): 4 had ventricular
tachycardia, 1 ventricular fibrillation, and 1 high-degree
atrioventricular block. In group 2, 11 patients (25%) had
malignant arrhythmias: 7 high-degree atrioventricular block, 3
ventricular tachycardia, and 1 ventricular fibrillation. Thus,
patients with BrPh had a higher likelihood of developing
Table 3. Clinical Characteristics in Patients With (Group 1) Versus Without Brugada Phenotype Pattern (Group 2) in the Presence
of Severe Hyperkalemia
Clinical Characteristics and Outcome
Group 1 Hyperkalemic Brugada
Phenotype (n=15)
Group 2 Hyperkalemic Non-Brugada
Phenotype (n=44) P Value
Age, y, median (IQR) 54 (41–62) 74 (60–83) 0.002
Female, n (%) 3 (20) 20 (46) 0.08
Hypertension, n (%) 7 (47) 31 (71) 0.06
Diabetes mellitus, n (%) 7 (47) 20 (45) 0.94
CKD, n (%) 3 (20) 23 (52) 0.04
Smoking, n (%) 4 (27) 12 (27) 0.92
Cardiac disease, n (%) 5 (33) 26 (59) 0.12
COPD, n (%) 1 (7) 11 (25) 0.15
BB, n (%) 3 (20) 17 (39) 0.19
ACE inhibitor, n (%) 5 (33) 9 (21) 0.53
ARB, n (%) 0 8 (18) 0.09
Mineralocorticoid antagonist, n (%) 3 (20) 6 (14) 0.48
Glycemia, mmol/L, median (IQR) 144 (101–272) 131 (105–185) 0.52
Crp, mg/dL, median (IQR) 3.2 (1.7–12.4) 2.5 (1.5–3.8) 0.31
(K), mmol/L, median (IQR) 7.7 (7.4–8.6) 6.9 (6.6–7.2) <0.001
Serum sodium, mmol/L, median (IQR) 132 (115–136) 133 (130–136) 0.12
Serum pH, median (IQR)* 7.07 (6.9–7.2) 7.25 (7.2–7.3) 0.003
HCO3, mEq/L, median (IQR)* 16 (5–20) 20 (15–27) 0.03
LVEF<60%, n (%) 0 11 (36) 0.03
Exitus, n (%) 6 (40) 18 (43) 0.85
ACE inhibitor indicates angiotensin-converting-enzyme use; ARB, angiotensin-receptor blocker use; BB, betablocking agent; CKD, chronic kidney disease; COPD, chronic obstructive
pulmonary disease; IQR, interquartile range; LVEF, left ventricular ejection fraction.
*Available in 49 patients.




Non-Brugada Phenotype (n=44) P Value
Heart rate, bpm, median (IQR) 87 (75–115) 80 (63–99) 0.20
P-wave voltage, mm, median (IQR) 0.5 (0.4–1.3) 0.5 (0.5–1.0) 0.67
PR segment, ms, median (IQR) 160 (160–210) 160 (120–180) 0.32
QRS abnormal axis, n (%) 8 (57.1) 17 (38.6) 0.01
QRS width, ms, median (IQR) 130 (110–160) 100 (80–120) 0.03
QTc segment, ms, median (IQR) 425 (368–475) 415 (390–450) 0.68
T-wave height, mm, median (IQR) 7.5 (5.4–14.5) 4 (2.5–6.0) 0.001
IQR indicates interquartile range.
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malignant arrhythmias. Nevertheless, total in-hospital mortal-
ity was similar (P<0.9) in both groups: 6 patients in group 1
(43%) versus 18 patients in group 2 (41%).
Hyperkalemia, Fibrosis, and the Mechanism of
BrPh
To differentiate between the mechanisms underlying BrPh
versus non-Brugada ECGs during hyperkalemia, we simulated
the effects of increasing [K+]o in a human wedge model of the
anterior ventricular walls, including the RVOT. Elevating the
[K+]o reduced the resting membrane potential throughout
from 87.90.1 mV at [K+]o=5.4 mmol/L to 69.930.08
mV at [K+]o=10.5 mmol/L, regardless of whether or not the
RVOT was fibrotic. As expected, the depolarized resting
potential reduced the availability of the sodium channels
and slowed the conduction velocity (CV). Figure 3A shows
activation sequences and V1 to V3 recordings for 4
different [K+]o (5.4, 7.5, 10.0, and 10.5 mmol/L) in the
presence and absence of fibrosis at the RVOT. Conduction at
the RVOT was significantly altered at 65% fibrosis, with
changes in the activation sequence that promoted the
appearance of late and fractionated potentials on V1 to V3.
There was a progressive slowing of conduction with increas-
ing [K+]o. At 5.4 mmol/L, CV at the RVOT in the absence of
fibrosis was 97.89 versus 60.81 cm/s when fibrosis was
included. In hyperkalemic conditions ([K+]o=10.0 mmol/L),
CV was 57.53 cm/s at baseline versus 28.66 cm/s in the
fibrotic RVOT. Increasing [K+]o to 10.5 mmol/L reduced CV
to 47.22 cm/s at baseline, but produced unexcitability and
propagation failure in the fibrotic RVOT. A similar progression
was also apparent on the V1, V2, and V3 recordings for each
[K+]o and normal/fibrotic state. Notable changes occurred on
leads V1 and V2, where there was delayed activation at the
Figure 3. Computer simulations testing the role of fibrosis of the right ventricular outflow tract (RVOT) at different levels of hyperkalemia. A,
Activation isochrones maps of the anterior wall with healthy (upper) and fibrotic RVOT (bottom), under basal conditions with extracellular
potassium concentration ([K+]o)=5.4 mmol/L and hyperkalemic conditions with [K
+]o=7.5 mmol/L, [K
+]o=10.0 mmol/L, and [K
+]o=10.5 mmol/L.
Pseudo-ECGs of V1, V2, and V3 leads are shown in each case. B, Action potential duration (APD) maps and corresponding action potential
signals of sites a, b, and c are shown in each case.
DOI: 10.1161/JAHA.118.010115 Journal of the American Heart Association 7
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RVOT, which prolonged the QRS interval proportionately.
Moreover, the ST-segment elevated and gradually fussed with
the T wave as the [K+]o increased. In the absence of fibrosis,
at [K+]o=10.0 mmol/L, the model reproduced the character-
istic features of hyperkalemia in patients with healthy RVOT.
In contrast, in the fibrotic case, conduction slowing or block
promoted ST-segment elevation on V1 and V2, consistent
with the classical BrS descriptors. In Figure 3B, the corre-
sponding action potential duration (APD) maps show a
progressive global decrease in the APD as [K+]o is increased.
As illustrated also by the action potential recordings at
specific locations, fibrosis intensified both the APD shorten-
ing and the activation delay at the RVOT and its immediate
vicinity.
Role of Ito
Previous evidence has implicated the epicardial-to-endocar-
dial Ito gradient within the right ventricle in the pathogenesis
and phenotypic expression of BrS.2 We therefore conducted
additional simulations to test the consequences of combining
hyperkalemia with increased epicardial Ito gradient at the
RVOT in the presence and absence of fibrosis. The gradient
was established by increasing the baseline value of the
epicardial band to 0.30, 0.70, and 1.50 mS/lF, while leaving
the endocardium at the basal level (0.08 mS/lF). In
Figure 4A, under basal [K+]o conditions, we had to increase
the maximal Ito conductance up to 1.50 mS/lF, to enable
BrPh, a value that is characteristic of BrS modeling.4
Increasing Ito produced a progressively exaggerated action
potential notch (arrow) at the RVOT while the rest of the
tissue was undergoing initial depolarization during the plateau
(Figure 4B). On the electrograms, these events coincided with
ST-segment elevation (Figure 4A).
As illustrated in Figure 5, the combined effects of fibrosis,
elevated [K+]o-induced membrane depolarization leading to
reduced excitability, and increased Ito density greatly facili-
tated the appearance of BrPh on leads V1 to V2. In Figure 5A,
a BrPh pattern was already evident on V1 and V2 at 55%
fibrosis even when the epicardial Ito was at baseline
(0.08 mS/lF). The effect was even greater when fibrosis at
the RVOT was increased to 75%. Here, ST-segment elevation
occurred at 10 mmol/L [K+]o because of extreme conduction
delay at the RVOT (Figure 5B).
In additional simulations, we assessed the effects of fibrosis
and Ito current gradient on the entire ventricular wall. The
effects were similar to those observedwhen such changeswere
only applied to the RVOT. The relative increase in Ito over the
entire epicardial surface with respect to the endocardium
simulated characteristics of the Brugada pattern (Figure 6). At
baseline, the Ito gradient caused an increase in the duration of
the epicardial action potential by increasing the transmem-
brane potassium outflow during the whole plateau phase. This
slightly elevated the ST segment and decreased the T-wave
amplitude, even depressing the T wave on V3. However, the
[K+]o increase also depolarized the membrane potential and
reduced the availability of the sodium channels. Consequently,
conduction velocity was reduced and the APD was abbreviated,
with the appearance of regions of activation failure. Fibrosis
throughout the ventricular surface slowed activation and
Figure 4. Computer simulations testing the role of incremental transient outward current (Ito) conductance. A, Activation isochrones maps of
the anterior right ventricular outflow tract (RVOT) wall with increasing the maximal conductance of Ito in the RVOT epicardium, from its basal
level to a characteristic value in BrS modeling (from 0.08 to 1.50 mS/lF, showing 0.30 and 0.70 mS/lF), under severe hyperkalemia
(extracellular potassium concentration [K+]o=10.5 mmol/L). Pseudo-ECGs of V1, V2, and V3 leads are shown in each case. B, Action potential
duration (APD) maps and corresponding action potential signals of sites a, b, and c are shown in each case. BrS indicates Brugada syndrome.
DOI: 10.1161/JAHA.118.010115 Journal of the American Heart Association 8
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wavefront propagation (Figure 7), prolonging the QRS and
delaying T-wave activation more than when fibrosis was
present in the RVOT. When the [K+]o was raised to a
pathological threshold, conduction slowed further with
propagation failure in areas with less excitable cardiac
tissue, including the RVOT and its surroundings. ST-segment
elevation did not occur under these conditions because of
the conduction slowing generated.
Figure 5. Computer simulations testing the role of incremental fibrosis, transient outward current (Ito) conductance, and extracellular
potassium concentration ([K+]o) conditions. A, Activation isochrones maps of the anterior right ventricular outflow tract (RVOT) wall with
different degrees of fibrosis (55, 65, and 75%), at baseline and severe [K+]o concentrations (5.4 and 10.5 mmol/L, respectively), combined with
2 values of maximal conductance of Ito: basal (0.08 mS/lF) or increased (0.50 mS/lF). Pseudo-ECGs of V1, V2, and V3 leads are shown in
each case. B, Action potential duration (APD) maps and corresponding action potential signals of sites a, b, and c are shown in each case.
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Proarrhythmic Risk of BrPh Pattern Attributed to
Hyperkalemia
The foregoing simulations provide insight into the mechanism
underlying the observed predisposition of BrPh patients to
malignant arrhythmias, as illustrated in the following clinical
example: Patient 5 (Table 1) arrived at the emergency
department after suffering an out-of-hospital sudden death
episode, showing complex ventricular rhythm with wide QRS.
An intravenous bolus of adenosine (12 mg) transiently slowed
the rhythm and normalized the QRS complex duration. When
the adenosine effect faded, the ventricular rhythm accelerated
and resumed with progressive QRS widening (Figure 8A
through 8C). The patient had a low conscience level, was
tachypneic, and had a blood pressure of 100/55 mm Hg.
Urgent blood analyses showed serum K+ levels of 9.1 mmol/L.
He was treated with intravenous fluids (2 L of glucosaline),
intravenous sodium bicarbonate, 1 g of intravenous calcium
chloride, and insulin. One hour later, the K+ level was
8.1 mmol/L and the ECG showed a BrPh pattern (Figure 8C).
The observed changes were consistent with adenosine
activation of IK,Ado channels, which, by increasing K
+ conduc-
tance, hyperpolarized the cell membrane, abbreviated the APD
and the refractory period, and inhibited spontaneous pacemaker
discharge, leading to significant QRS narrowing and transient
sinus arrest.27 This finding was further confirmed by our
computer simulations. In Figure 9, we used a fibrotic RVOT with
hyperkalemic conditions at [K+]o=10.0 mmol/L. A burst stimu-
lus train with an extra stimulus at 400 ms increased electrogram
fractionation and caused unidirectional block that allowed stable
reentry formation at the RVOT.
Discussion
The main findings of this study are as follows: 1. In patients
with severe hyperkalemia resulting from a critical medical
condition, the presence of a BrS phenotype is associated with
a high prevalence of malignant arrhythmias and all-cause
mortality. 2. In surviving patients, the characteristic Brugada
ECG changes are transient and disappear when the serum K+
levels normalize. 3. In patients with BrS, hyperkalemia may
elicit the typical BrS ECG manifestations. 4. Higher serum K+
Figure 6. Computer simulations testing the role of gradient of Ito conductance over the entire epicardial
surface at different levels of extracellular potassium concentration ([K+]o). A, Activation isochrones maps
with Ito maximal conductance in the whole epicardium to a characteristic value in BrS modeling (1.50 mS/
lF), under basal conditions ([K+]o=5.4 mmol/L) and hyperkalemic conditions ([K
+]o=10.5 mmol/L).
Pseudo-ECGs of V1, V2, and V3 leads are shown in each case. B, Action potential duration (APD) maps and
corresponding action potential signals of sites a, b, and c are shown in each case. BrS indicates Brugada
syndrome; Ito, transient outward current.
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 http://ahajournals.org by on M
ay 6, 2020
levels and male sex were independent predictors for the
presence of BrPh ECG in patients with severe hyperkalemia.
5. As shown by the response to adenosine infusion and
computer simulations, ECG manifestations of systemic hyper-
kalemia are a consequence of the depolarized resting
membrane potential and reduced sodium-channel availability
for action potential activation, which results in delayed and
heterogeneous conduction, or block, particularly in the
presence of fibrosis at the RVOT.
Systemic Hyperkalemia Causing BrPh
Systemic hyperkalemia is most frequently found in patients
with chronic and acute renal failure and/or concomitant
treatments with nephrotoxic medications or K-sparing drugs.
The classical electrocardiographic manifestations of hyper-
kalemia were first documented in the early 1950s by the
presence of peaked T waves, shortened QT interval, length-
ening of the PR interval, loss of P waves, and widening of the
QRS complex.28 Moreover, Levine et al also described the
presence of the “dialyzable” current of injury resembling acute
myocardial infarction or pericarditis.29 However, Littmann
et al reported the first consecutive series that recognized the
similarities between the classic BrS ECG manifestations and
those occasionally shown in the context of severe hyper-
kalemia.11 In agreement with this and other studies,10,11,30 we
found that BrPh was most likely present in critically ill male
patients with severe decompensation of their renal function
and/or malignancies, with high mortality mostly related to
their underlying clinical condition. In addition, we found that
compared with hyperkalemic patients without Brugada ECG,
the BrPh patients presented in males with higher serum K+
values (1 mmol/L higher on average). Moreover, lower pH
was also strongly related to the development of BrPh. These
data, together with the presence of other outcome predictors,
such as younger age, lower hypertension prevalence, and
lesser chronic renal disease, further confirm the importance
of acute increments in K+ levels, which might be underesti-
mated in terminal renal failure patients.31 Given that the
density of the strong inward rectifying K+ current, IK1, which
maintains the resting membrane potential of the ventricular
myocyte, is strictly controlled by [K+]o, acute increases in
[K+]o, however transient, may place such patients at risk of
malignant arrhythmias.32 The findings of our multivariant
analyses further support the predominant role of male sex and
higher hyperkalemia levels, together with the role for the acid
Figure 7. Computer simulations testing the role of fibrosis over the entire epicardial surface at
different levels of extracellular potassium concentration ([K+]o). A, Activation isochrones maps
with fibrosis in the whole (65%), under basal conditions ([K+]o=5.4 mmol/L) and hyperkalemic
conditions ([K+]o=10.5 mmol/L). Pseudo-ECGs of V1, V2, and V3 leads are shown in each case.
B, Action potential duration (APD) maps and corresponding action potential signals of sites a, b,
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group presence on the reduction of channel conductance
favoring the occurrence of malignant ventricular arrhythmias,
as shown in our simulations.33
We compared the clinical manifestations, ECG, and out-
comes (malignant arrhythmias and mortality) of BrPh patients
with those of severe hyperkalemic patients (K+ ≥6.5 mmol/L)
without BrS phenotype. Overall, patients with the BrPh ECG had
a grave prognosis with a short- to mid-term fatality rate of 51%
not only related to the baseline clinical disease, but also to the
clinical impact of malignant ventricular arrhythmias. Moreover,
although patients presenting with BrPh had a higher likelihood
of developing malignant arrhythmias than non-BrPh patients
(43% versus 25%), in-hospital mortality was similar because of
the poor clinical status in both groups. Junttila et al 34 reported
on a series of patients with typical Brugada-type ECG during an
acute medical event (including 5 patients with electrolyte
imbalance), where 51% presented malignant arrhythmias and
38% developed sudden cardiac arrest. Unfortunately, in that
report, only a minority of patients had a confirmed BrS genetic
test. In our cohort of surviving patients, the characteristic BrS
ECG changes disappeared when K+ levels normalized. We
attempted to perform a flecainide test after serum K+ levels
became normal and found a BrS typical ECG that was
unmasked by the hyperkalemic state. Postema et al35 previ-
ously reported a similar case of diabetic ketoacidosis with
concomitant hyperkalemia that uncovered a typical BrS.
We compared the ECG of hyperkalemic patients and found
that patients showing a BrPh had a wider QRS, and frequently
presented abnormal QRS axis and a greater T-wave height
compared with non-BrPh hyperkalemic patients (Table 3). This
contrasted with patients with inheritable BrS that usually have
mildly widened QRS complexes, but normal QRS axes on an
otherwise normal ECG.11,36 Thus, the presence of moderate-
to-severe hyperkalemia, especially with a Brugada ECG
pattern or atypical ST-segment elevation on the right precor-
dial leads without BrS, should be aggressively treated and
considered a risk factor for development of life-threatening
cardiac arrhythmias. This is in agreement with previous
studies showing that presence of an aVR sign and/or ST-
segment elevation on the right precordial leads pattern
reflects more right ventricular conduction delay and electrical
heterogeneity, increasing the risk for developing arrhythmic
events.18,19
Mechanism of Proarrhythmic Risk of BrPh Pattern
Attributed to Hyperkalemia
To our knowledge, the relationship between hyperkalemia and
the BrS ECG manifestations had not yet been systematically
investigated. Together, the clinical results and computer
simulations presented above provide mechanistic insight into
the manifestation of electrolytic dysregulation causing Bru-
gada phenotype. Even in the absence of genetic disease (eg,
inheritable SCN5A mutations), delays in ventricular activation,
and propagation failure at the RVOT, magnified by the
presence of hyperkalemia and, possibly, low acid base state,
promote the required electrophysiological changes, including
APD shortening, membrane depolarization, and reduced sodium-
channel availability, which enable the manifestation of BrPh ECG,
an effect that is magnified by RVOT fibrosis. Introduction of
Figure 8. Wide complex tachycardia response to adenosine in a patient with severe hyperkalemia. A, Wide complex tachycardia upon arrival
(serum potassium [K]=9.1 mmol/L). B, ECG recording during peak adenosine effect showing sinus arrest and significant QRS narrowing,
followed by accelerated ventricular rhythm with progressive QRS widening later after disappearance of the adenosine effect. C, One hour later,
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fibrotic tissue reduced the excitability of the RVOT and slowed
CV, leading to a ST-segment elevation on V1 and V2 leads,
creating the substrate for inducibility of malignant arrhythmias.
In agreement with previous clinical reports, computer simula-
tions showed that programmed stimulation caused electrogram
fractionation and unidirectional block to initiate stable reentry
formation without the need of an extrasytole.8 Unexcitability
attributed to the high concentration of potassium and its
propensity to the generation of arrhythmias agrees with recent
reports.12 These results are supported by simulations by other
groups showing that activation delay and right ventricular
excitation failure attributed to current-load mismatch secondary
to decrease in calcium current or increase in Ito can cause
BrS.16,17 Similar mechanisms could be responsible for other
types of BrPh, with low availability of sodium channels given that
it occurs during hypothermia or acidosis in ischemic regions.
The relative increase in Ito density at the RVOT reduced the
need for slow conduction caused by hyperkalemia and resulted
in spatial gradients of membrane voltage giving rise to the
typical ST-segment elevation found in BrPh. In agreement with
BrS, the strong sex-related predominance found in the BrPh
indirectly supports the prominence of the transient outward
current-mediated action potential notch in the right ventricular
epicardium of males.37 Moreover, the combination of abnormal
repolarization and abnormal conduction not only explains the
phenotypic manifestation of the BrPh, but also its clinical
arrhythmic outcomes in the form of sustained ventricular
reentrant patterns. On one hand, the presence of steep
repolarization gradients causes asymmetry in excitability that
gives rise to unidirectional block. On the other, slow conduction
shortens the wavelength of the reentrant AP facilitating
reentrant stabilization (Figures 8 and 9). Therefore, severe
hyperkalemia leading to inactivation of the sodium channel in
conjunction with presence of subtle structural abnormalities of
the FVOT were responsible for the BrPh manifestation and
reentrant arrhythmia occurrence in this setting.
Limitations
The observational and retrospective nature of the study
prevented clinical data collections (ie, acid group value) and
reduced the number of available ECGs. Although the
computer simulations support the theory that RVOT has a
major role producing Brugada patterns, further clinical data
(histological and image data) and cellular studies are neces-
sary to accurately define the substrate of this clinical entity in
Figure 9. Monomorphic ventricular tachycardia induction during burst stimulation train followed by an extrastimuli at 400 ms allowed a stable
reentry formation at the right ventricular outflow tract (RVOT) fibrotic site in a model with hyperkalemic conditions and extracellular potassium
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this environment.15,38 For example, imaging (eg, magnetic
resonance imaging) data in patients presenting with a BrPh
ECG could have shown enhanced fibrosis in the RVOT, as
predicted by the modeling results. However, magnetic reso-
nance imaging was nearly impossible in our study because of
the fact that many of the patients were critically ill and had a
very poor outcome, which substantially limited the number of
patients available to study.
Conclusion
This report adds to our understanding of the electrocardio-
graphic features of hyperkalemic BrPh patients. In patients
with severe hyperkalemia attributed to critical medical
conditions, a BrPh ECG is associated with a high prevalence
of malignant arrhythmias and high all-cause mortality. BrPh
ECG manifestations in patients with hyperkalemia are
attributed to depolarized resting membrane potential and
reduced availability of inward sodium channels. Although Ito
elevation contributes, it is not essential to generate the
hyperkalemic Brugada phenotype.
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